These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34358767)

  • 1. The dual orexin receptor antagonist almorexant blocks the sleep-disrupting and daytime stimulant effects of methamphetamine in rhesus monkeys.
    Berro LF; Moreira-Junior EDC; Rowlett JK
    Drug Alcohol Depend; 2021 Oct; 227():108930. PubMed ID: 34358767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of tolerance to the effects of methamphetamine on daytime and nighttime activity evaluated with actigraphy in rhesus monkeys.
    Berro LF; Andersen ML; Howell LL
    Psychopharmacology (Berl); 2017 Aug; 234(15):2277-2287. PubMed ID: 28589263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users.
    Cruz HG; Hoever P; Chakraborty B; Schoedel K; Sellers EM; Dingemanse J
    CNS Drugs; 2014 Apr; 28(4):361-72. PubMed ID: 24627301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of methadone, buprenorphine, and naltrexone on actigraphy-based sleep-like parameters in male rhesus monkeys.
    Berro LF; Zamarripa CA; Talley JT; Freeman KB; Rowlett JK
    Addict Behav; 2022 Dec; 135():107433. PubMed ID: 35901553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a Serotonin 2C Agonist and a 2A Antagonist on Actigraphy-Based Sleep Parameters Disrupted by Methamphetamine Self-Administration in Rhesus Monkeys.
    Perez Diaz M; Andersen ML; Rice KC; Howell LL
    Neuropsychopharmacology; 2017 Jun; 42(7):1531-1538. PubMed ID: 27986974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) and R(-) MDMA on actigraphy-based daytime activity and sleep parameters in rhesus monkeys.
    Berro LF; Shields H; Odabas-Geldiay M; Rothbaum BO; Andersen ML; Howell LL
    Exp Clin Psychopharmacol; 2018 Aug; 26(4):410-420. PubMed ID: 29939048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors.
    Mang GM; Dürst T; Bürki H; Imobersteg S; Abramowski D; Schuepbach E; Hoyer D; Fendt M; Gee CE
    Sleep; 2012 Dec; 35(12):1625-35. PubMed ID: 23204605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists.
    Malherbe P; Borroni E; Pinard E; Wettstein JG; Knoflach F
    Mol Pharmacol; 2009 Sep; 76(3):618-31. PubMed ID: 19542319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orexin Receptor Antagonism Improves Sleep and Reduces Seizures in Kcna1-null Mice.
    Roundtree HM; Simeone TA; Johnson C; Matthews SA; Samson KK; Simeone KA
    Sleep; 2016 Feb; 39(2):357-68. PubMed ID: 26446112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Orexin Receptor Antagonist, Almorexant, in Elderly Patients With Primary Insomnia: A Randomized, Controlled Study.
    Roth T; Black J; Cluydts R; Charef P; Cavallaro M; Kramer F; Zammit G; Walsh J
    Sleep; 2017 Feb; 40(2):. PubMed ID: 28364509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference.
    Black J; Pillar G; Hedner J; Polo O; Berkani O; Mangialaio S; Hmissi A; Zammit G; Hajak G
    Sleep Med; 2017 Aug; 36():86-94. PubMed ID: 28735928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine.
    Cruz HG; Hay JL; Hoever P; Alessi F; te Beek ET; van Gerven JM; Dingemanse J
    Eur Neuropsychopharmacol; 2014 Aug; 24(8):1257-68. PubMed ID: 24880753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant.
    Dietrich H; Jenck F
    Psychopharmacology (Berl); 2010 Oct; 212(2):145-54. PubMed ID: 20631993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Actigraphy-based sleep parameters during the reinstatement of methamphetamine self-administration in rhesus monkeys.
    Berro LF; Andersen ML; Tufik S; Howell LL
    Exp Clin Psychopharmacol; 2016 Apr; 24(2):142-6. PubMed ID: 26882419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GABA
    Berro LF; Andersen ML; Tufik S; Howell LL
    Neuropharmacology; 2017 Sep; 123():299-309. PubMed ID: 28495376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability, pharmacokinetics, and pharmacodynamics of single-dose almorexant, an orexin receptor antagonist, in healthy elderly subjects.
    Hoever P; Hay J; Rad M; Cavallaro M; van Gerven JM; Dingemanse J
    J Clin Psychopharmacol; 2013 Jun; 33(3):363-70. PubMed ID: 23609389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the effect of the dual orexin receptor antagonist almorexant on ophthalmological, spermatogenic, and hormonal variables in healthy male subjects.
    Dingemanse J; Charef P; Black J; Gouws C
    Biomed Pharmacother; 2021 Jan; 133():110955. PubMed ID: 33190032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice.
    Mahoney CE; Mochizuki T; Scammell TE
    Sleep; 2020 Jun; 43(6):. PubMed ID: 31830270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant.
    Hoever P; de Haas S; Winkler J; Schoemaker RC; Chiossi E; van Gerven J; Dingemanse J
    Clin Pharmacol Ther; 2010 May; 87(5):593-600. PubMed ID: 20376002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studies.
    Dingemanse J; Gehin M; Cruz HG; Hoever P
    Drug Des Devel Ther; 2014; 8():397-403. PubMed ID: 24812492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.